The National Institutes of Health (NIH) has suspended a grant of $ 9 million for a study of depression conducted by a psychiatrist at the Emory University in Atlanta. The punishment imposed in August but only made public today, is apparently the most severe reaction by the NIH to present at a Senate investigation of the NIH-funded researchers who may have failed to report all of their income companies pharmaceuticals.
Since last spring, Senator Charles Grassley (R-IA) registered at least nine academic psychiatrists not to follow the federal rules that require recipients of NIH to report industry consulting income their institutions. A researcher at Stanford University was removed from a NIH grant. The most recent revelations involve Charles Nemeroff Emory, who reportedly only 1.2 million $ 2.4 million less than the pharmaceutical companies and device Grassley said they paid between 00 and 07. $
Nemeroff is "voluntarily stepping aside" all grants from NIH on which he was the leader or co-investigator, said in a statement Emory, after leaving his post as chairman of the psychiatry department. NIH recently called Nemeroff be removed from three research grants and training awards "until there's resolution" concerns, said David Wynes, vice president for research administration at Emory, which launched . besides its own investigation, the NIH stopped the funding for a grant - a study of $ 9.3 million (the suspended grant was announced today by Atlanta Journal-Constitution .) 5-year clinical depression that began in 06.
the study of depression is to enroll 0 patients in a 12-week study testing two psychotropic medication and cognitive behavioral therapy. Co-researchers use genetic testing, personality assessments and brain imaging to learn which of these treatments work best. Wynes said less than a dozen patients were enrolled, although those still in treatment continue to receive. NIH suspended payment in mid-August
It is not known exactly why NIH suspended this particular grant. Nemeroff consulted for Eli Lilly, which is one of the tested drug, duloxetine, but his recent income fell below an annual reporting threshold of $ 10,000. The other drug, escitalopram, is manufactured by Forest Laboratories; this company does not appear on the countdown Grassley 2.4 million at least $ payments to Nemeroff.
Emory faculty also informed last week that NIH is imposing "special award conditions" on all grants. The university says it must check that all new grant researchers have filed disclosures and describe the conflict as well as Emory took action to manage. Normally, universities should not give these details NIH.
A spokesman declined to comment NIH suspended the grant. The agency is expected to issue an opinion soon ask for feedback on ways to strengthen the regulation of conflicts of interest applicable to the recipients of the NIH.
NIH had resisted the pressure Grassley to suspend subsidies for violations conflicts. NIH Director Elias Zerhouni told reporters last month that "you have to be careful" because stopping a clinical trial can affect the treatment of patients with serious diseases. "This is not a decision to light," said Zerhouni, who is retiring this month.
0 Komentar